CA1233748A - Produits et methodes pour le traitement du cancer - Google Patents

Produits et methodes pour le traitement du cancer

Info

Publication number: CA1233748A
Authority: CA; Canada
Prior art keywords: protein; tumor; igg; serum; sera
Prior art date: 1982-04-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000529504A

Other languages

English (en)

Inventor

David S. Terman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Baylor College of Medicine

Original Assignee

Baylor College of Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-04-07

Filing date

1987-02-11

Publication date

1988-03-08

1983-04-06 Priority claimed from CA000425324A external-priority patent/CA1230555A/fr

1987-02-11 Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine

1987-02-11 Priority to CA000529504A priority Critical patent/CA1233748A/fr

1988-03-08 Application granted granted Critical

1988-03-08 Publication of CA1233748A publication Critical patent/CA1233748A/fr

Status Expired legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 186
238000000034 method Methods 0.000 title claims abstract description 44
201000011510 cancer Diseases 0.000 title claims abstract description 21
238000011282 treatment Methods 0.000 title abstract description 43
229920000392 Zymosan Polymers 0.000 claims abstract description 20
210000002966 serum Anatomy 0.000 claims description 124
230000000694 effects Effects 0.000 claims description 45
238000002360 preparation method Methods 0.000 claims description 41
230000000295 complement effect Effects 0.000 claims description 35
239000000126 substance Substances 0.000 claims description 7
238000001727 in vivo Methods 0.000 claims description 5
239000006227 byproduct Substances 0.000 claims description 4
230000003033 spasmogenic effect Effects 0.000 claims description 4
206010047141 Vasodilatation Diseases 0.000 claims description 3
230000008569 process Effects 0.000 claims description 2
238000006243 chemical reaction Methods 0.000 abstract description 22
230000002476 tumorcidal effect Effects 0.000 abstract description 18
239000000203 mixture Substances 0.000 abstract description 17
206010025323 Lymphomas Diseases 0.000 abstract description 15
230000000259 anti-tumor effect Effects 0.000 abstract description 7
239000002246 antineoplastic agent Substances 0.000 abstract description 2
229940127089 cytotoxic agent Drugs 0.000 abstract description 2
230000002459 sustained effect Effects 0.000 abstract description 2
102000004169 proteins and genes Human genes 0.000 description 160
108090000623 proteins and genes Proteins 0.000 description 160
235000018102 proteins Nutrition 0.000 description 159
241000282465 Canis Species 0.000 description 70
230000027455 binding Effects 0.000 description 62
241000282472 Canis lupus familiaris Species 0.000 description 58
230000010412 perfusion Effects 0.000 description 58
241000282414 Homo sapiens Species 0.000 description 57
238000009739 binding Methods 0.000 description 55
108060003951 Immunoglobulin Proteins 0.000 description 49
102000018358 immunoglobulin Human genes 0.000 description 49
210000004027 cell Anatomy 0.000 description 43
239000000047 product Substances 0.000 description 41
229920001223 polyethylene glycol Polymers 0.000 description 37
239000002244 precipitate Substances 0.000 description 36
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
239000000872 buffer Substances 0.000 description 29
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
102100031506 Complement C5 Human genes 0.000 description 20
238000001802 infusion Methods 0.000 description 20
239000006228 supernatant Substances 0.000 description 20
201000008274 breast adenocarcinoma Diseases 0.000 description 17
102100022133 Complement C3 Human genes 0.000 description 16
239000003610 charcoal Substances 0.000 description 16
238000001962 electrophoresis Methods 0.000 description 15
108010074605 gamma-Globulins Proteins 0.000 description 15
241001465754 Metazoa Species 0.000 description 14
210000003743 erythrocyte Anatomy 0.000 description 14
239000000725 suspension Substances 0.000 description 14
229930006000 Sucrose Natural products 0.000 description 13
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 13
150000002500 ions Chemical class 0.000 description 13
230000020477 pH reduction Effects 0.000 description 13
230000002269 spontaneous effect Effects 0.000 description 13
239000005720 sucrose Substances 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
102000006395 Globulins Human genes 0.000 description 12
108010044091 Globulins Proteins 0.000 description 12
241000283973 Oryctolagus cuniculus Species 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
239000000306 component Substances 0.000 description 12
208000032839 leukemia Diseases 0.000 description 12
238000005194 fractionation Methods 0.000 description 11
239000000463 material Substances 0.000 description 11
239000012528 membrane Substances 0.000 description 11
206010006187 Breast cancer Diseases 0.000 description 10
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 10
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
229960004397 cyclophosphamide Drugs 0.000 description 10
108010088751 Albumins Proteins 0.000 description 9
102000009027 Albumins Human genes 0.000 description 9
239000000427 antigen Substances 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
229940072221 immunoglobulins Drugs 0.000 description 9
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 9
230000009467 reduction Effects 0.000 description 9
230000004044 response Effects 0.000 description 9
241000894007 species Species 0.000 description 9
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 8
108010024976 Asparaginase Proteins 0.000 description 8
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 8
230000024203 complement activation Effects 0.000 description 8
239000012634 fragment Substances 0.000 description 8
210000000440 neutrophil Anatomy 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
230000001154 acute effect Effects 0.000 description 7
230000003171 anti-complementary effect Effects 0.000 description 7
238000005119 centrifugation Methods 0.000 description 7
230000004087 circulation Effects 0.000 description 7
231100000433 cytotoxic Toxicity 0.000 description 7
230000001472 cytotoxic effect Effects 0.000 description 7
230000007423 decrease Effects 0.000 description 7
230000002950 deficient Effects 0.000 description 7
238000010494 dissociation reaction Methods 0.000 description 7
230000005593 dissociations Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
238000011534 incubation Methods 0.000 description 7
238000006386 neutralization reaction Methods 0.000 description 7
238000001556 precipitation Methods 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
125000006850 spacer group Chemical class 0.000 description 7
102000004506 Blood Proteins Human genes 0.000 description 6
108010017384 Blood Proteins Proteins 0.000 description 6
206010028851 Necrosis Diseases 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000008859 change Effects 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
230000017074 necrotic cell death Effects 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000000758 substrate Substances 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
108010089414 Anaphylatoxins Proteins 0.000 description 5
241000282412 Homo Species 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
241001529936 Murinae Species 0.000 description 5
241000191967 Staphylococcus aureus Species 0.000 description 5
229940009456 adriamycin Drugs 0.000 description 5
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
229910052921 ammonium sulfate Inorganic materials 0.000 description 5
235000011130 ammonium sulphate Nutrition 0.000 description 5
201000008275 breast carcinoma Diseases 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
210000000265 leukocyte Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000004848 nephelometry Methods 0.000 description 5
230000002093 peripheral effect Effects 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
239000011800 void material Substances 0.000 description 5
201000003076 Angiosarcoma Diseases 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
241000700199 Cavia porcellus Species 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
208000001258 Hemangiosarcoma Diseases 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
241000191940 Staphylococcus Species 0.000 description 4
208000009956 adenocarcinoma Diseases 0.000 description 4
230000004520 agglutination Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
239000000470 constituent Substances 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
230000003013 cytotoxicity Effects 0.000 description 4
231100000135 cytotoxicity Toxicity 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000002497 edematous effect Effects 0.000 description 4
230000002526 effect on cardiovascular system Effects 0.000 description 4
229960001340 histamine Drugs 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
238000002955 isolation Methods 0.000 description 4
210000001165 lymph node Anatomy 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
238000002203 pretreatment Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
102000005600 Cathepsins Human genes 0.000 description 3
108010084457 Cathepsins Proteins 0.000 description 3
241000700198 Cavia Species 0.000 description 3
240000003550 Eusideroxylon zwageri Species 0.000 description 3
108010058683 Immobilized Proteins Proteins 0.000 description 3
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
102000003896 Myeloperoxidases Human genes 0.000 description 3
108090000235 Myeloperoxidases Proteins 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
229920005654 Sephadex Polymers 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
238000010306 acid treatment Methods 0.000 description 3
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
210000003714 granulocyte Anatomy 0.000 description 3
230000002949 hemolytic effect Effects 0.000 description 3
239000005457 ice water Substances 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000010166 immunofluorescence Methods 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
230000004660 morphological change Effects 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
238000010979 pH adjustment Methods 0.000 description 3
230000037361 pathway Effects 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
230000001373 regressive effect Effects 0.000 description 3
238000004062 sedimentation Methods 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
-1 superoxide anions Chemical class 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000002861 ventricular Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
238000011640 AKR mouse Methods 0.000 description 2
208000000104 Arthus reaction Diseases 0.000 description 2
102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
101100087530 Caenorhabditis elegans rom-1 gene Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
102000016574 Complement C3-C5 Convertases Human genes 0.000 description 2
108010067641 Complement C3-C5 Convertases Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
201000005505 Measles Diseases 0.000 description 2
101100305983 Mus musculus Rom1 gene Proteins 0.000 description 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
102000005686 Serum Globulins Human genes 0.000 description 2
108010045362 Serum Globulins Proteins 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
235000018259 Solanum vestissimum Nutrition 0.000 description 2
240000002825 Solanum vestissimum Species 0.000 description 2
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
206010053614 Type III immune complex mediated reaction Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
208000005298 acute pain Diseases 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
230000001147 anti-toxic effect Effects 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
150000004695 complexes Chemical class 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000002298 density-gradient ultracentrifugation Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000012636 effector Substances 0.000 description 2
230000005684 electric field Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
210000001723 extracellular space Anatomy 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
230000004927 fusion Effects 0.000 description 2
210000000224 granular leucocyte Anatomy 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
230000002008 hemorrhagic effect Effects 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
230000000544 hyperemic effect Effects 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
150000002482 oligosaccharides Polymers 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
210000004180 plasmocyte Anatomy 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
239000000376 reactant Substances 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000008728 vascular permeability Effects 0.000 description 2
230000024883 vasodilation Effects 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
108091005508 Acid proteases Proteins 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
KXLUWEYBZBGJRZ-POEOZHCLSA-N Canin Chemical compound O([C@H]12)[C@]1([C@](CC[C@H]1C(=C)C(=O)O[C@@H]11)(C)O)[C@@H]1[C@@]1(C)[C@@H]2O1 KXLUWEYBZBGJRZ-POEOZHCLSA-N 0.000 description 1
206010072960 Chest wall tumour Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
GPFVKTQSZOQXLY-UHFFFAOYSA-N Chrysartemin A Natural products CC1(O)C2OC2C34OC3(C)CC5C(CC14)OC(=O)C5=C GPFVKTQSZOQXLY-UHFFFAOYSA-N 0.000 description 1
241000767925 Collodes Species 0.000 description 1
241000518994 Conta Species 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
101150039033 Eci2 gene Proteins 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000002068 Glycopeptides Human genes 0.000 description 1
108010015899 Glycopeptides Proteins 0.000 description 1
101500028082 Homo sapiens C5a anaphylatoxin Proteins 0.000 description 1
101000637771 Homo sapiens Solute carrier family 35 member G1 Proteins 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100039352 Immunoglobulin heavy constant mu Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
101100536883 Legionella pneumophila subsp. pneumophila (strain Philadelphia 1 / ATCC 33152 / DSM 7513) thi5 gene Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
206010025327 Lymphopenia Diseases 0.000 description 1
241001024304 Mino Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241001163743 Perlodes Species 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
101100240664 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nmt1 gene Proteins 0.000 description 1
206010042135 Stomatitis necrotising Diseases 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
230000010398 acute inflammatory response Effects 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000719 anti-leukaemic effect Effects 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
210000003293 antilymphocyte serum Anatomy 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
238000010420 art technique Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
230000007681 cardiovascular toxicity Effects 0.000 description 1
231100000060 cardiovascular toxicity Toxicity 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000004154 complement system Effects 0.000 description 1
230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000000039 congener Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000050 cytotoxic potential Toxicity 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000011833 dog model Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000000909 electrodialysis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
230000012953 feeding on blood of other organism Effects 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
229940060415 hepatitis b immune globulin Drugs 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
230000009215 host defense mechanism Effects 0.000 description 1
102000053339 human SLC35G1 Human genes 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000004201 immune sera Anatomy 0.000 description 1
229940042743 immune sera Drugs 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000002624 low-dose chemotherapy Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
231100001023 lymphopenia Toxicity 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000006512 mast cell neoplasm Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
210000003622 mature neutrocyte Anatomy 0.000 description 1
239000012982 microporous membrane Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
230000003282 necrolytic effect Effects 0.000 description 1
208000018223 neoplasm of chest wall Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
201000008585 noma Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000021962 pH elevation Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000012071 phase Substances 0.000 description 1
HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229960000380 propiolactone Drugs 0.000 description 1
OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
229940070376 protein Drugs 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
239000004627 regenerated cellulose Substances 0.000 description 1
210000002254 renal artery Anatomy 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000011268 retreatment Methods 0.000 description 1
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000012358 sourcing Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
229940085526 tetanus immune globulin Drugs 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
229940041230 varicella-zoster immune globulin Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000013598 vector Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
208000037911 visceral disease Diseases 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000002023 wood Substances 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA000529504A 1982-04-07 1987-02-11 Produits et methodes pour le traitement du cancer Expired CA1233748A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000529504A CA1233748A (fr)	1982-04-07	1987-02-11	Produits et methodes pour le traitement du cancer

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US36643682A	1982-04-07	1982-04-07
US366,436		1982-04-07
US47236283A	1983-03-11	1983-03-11
US472,362		1983-03-11
CA000425324A CA1230555A (fr)	1982-04-07	1983-04-06	Produits et methodes pour le traitement du cancer
CA000529504A CA1233748A (fr)	1982-04-07	1987-02-11	Produits et methodes pour le traitement du cancer

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000425324A Division CA1230555A (fr)	1982-04-07	1983-04-06	Produits et methodes pour le traitement du cancer

Publications (1)

Publication Number	Publication Date
CA1233748A true CA1233748A (fr)	1988-03-08

Family

ID=27167336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000529504A Expired CA1233748A (fr)	1982-04-07	1987-02-11	Produits et methodes pour le traitement du cancer

Country Status (1)

Country	Link
CA (1)	CA1233748A (fr)

1987
- 1987-02-11 CA CA000529504A patent/CA1233748A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2005-03-08	MKEX	Expiry

Publication	Publication Date	Title
Salant et al.	1980	A new role for complement in experimental membranous nephropathy in rats.
US3758682A (en)	1973-09-11	Pharmaceutical compositions comprising orgotein and their use
US4699783A (en)	1987-10-13	Products and methods for treatment of cancer
Lance	1969	The mechanism of action of anti-lymphocyte serum: studies of antibody eluate
US5879679A (en)	1999-03-09	Antigen-based heteropolymers and method for treating autoimmune diseases using the same
Mannik et al.	1983	Rearrangement of immune complexes in glomeruli leads to persistence and development of electron-dense deposits.
Adler et al.	1983	Mediation of proteinuria in membranous nephropathy due to a planted glomerular antigen
Brown et al.	1970	The localization of immunoglobulin and immune complexes in lymphoid tissue
Natori et al.	1978	Immunochemical evidence of a tumor-specific surface antigen obtained by detergent solubilization of the membranes of a chemically induced sarcoma, Meth-A
Cunnington et al.	1981	Oxygen-binding and immunological properties of complexes between dextran and animal haemoglobins
Lassmann et al.	1983	In vivo demyelinating activity of sera from animals with chronic experimental allergic encephalomyelitis: antibody nature of the demyelinating factor and the role of complement
CA1230555A (fr)	1987-12-22	Produits et methodes pour le traitement du cancer
Howard et al.	1968	Prolongation of skin homografts by rabbit anti-mouse lymphocyte serum in mice rendered tolerant to rabbit γ-globulin
CA1233748A (fr)	1988-03-08	Produits et methodes pour le traitement du cancer
US4009257A (en)	1977-02-22	Preparation of immunosuppressive materials
Janeway Jr et al.	1975	The role of thymus‐derived lymphocytes in an antibody‐mediated hapten‐specific helper effect
Binns et al.	1972	Lymphoid depletion and immunosuppression after thymectomy in the young pig
CA1242392A (fr)	1988-09-27	Produits et methodes pour le traitement du cancer
Sato et al.	1988	Studies on the induction of tolerance to alloantigens. III. Induction of antibodies directed against alloantigen-specific delayed-type hypersensitivity T cells by a single injection of allogeneic lymphocytes via portal venous route.
US5004604A (en)	1991-04-02	Immuno-suppressive material and process for preparing same
Rossen et al.	1971	Preventing antibody formation to anti-lymphocytic globulin in man
Prager et al.	1973	Induction of immunity to a mouse lymphoma by multiple methods, including vaccination with soluble membrane fractions
Hirotsu et al.	1983	The mediation of tissue eosinophilia in hypersensitivity reactions. III. Separation of two different delayed eosinophil chemotactic factors and transfer of these factors by serum or cells from sensitized guinea-pigs
JPS58201717A (ja)	1983-11-24	腫瘍免疫製剤およびその製造方法
Jones et al.	1971	Reactions in vitro with target cells and subcellular fractions of enriched rat alloantibodies with enhancing activity